|A product of the Society of Infectious Diseases Pharmacists Education Center (SIDPEC)|
NOTE: If you attended this live CE activity that was held on November 6, 2021 at the SIDP Annual Meeting AND received CE credit (i.e. a pharmacist CE statement with ACPE Universal Activity Number 0221-9999-21-276-L01-P), you are NOT eligible to also receive CE credit for this home-study activity.
This blood boiling debate will try to convince participants of the utility or fatality of trusting ceftriaxone to treat MSSA bacteremia by reviewing both in vitro and in vivo literature.
This is a featured CE activity on the Society of Infectious Diseases Pharmacists Education Center (SIDPEC) website. SIDPEC is the educational hub of the Society of Infectious Diseases Pharmacists (SIDP). The SIDPEC portal provides educational activities on infectious disease pharmacotherapy for clinical pharmacists, health‐systems pharmacists, community pharmacists, and other allied‐health disciplines.
The target audience for this activity is pharmacists. At the completion of this activity, the participant will be able to:
- Discuss the pros and cons of using ceftriaxone for MSSA bacteremia.
- Review the literature surrounding ceftriaxone and alternative beta-lactam therapy for MSSA bacteremia.
- Identify clinical scenarios in which ceftriaxone may or may not be an appropriate choice for an MSSA infection.
Kira Beaulac, PharmD, BCIDP
Antimicrobial Stewardship Pharmacist
Jamie Wagner, PharmD, BCPS
Clinical Associate Professor of Pharmacy Practice
University of Mississippi School of Pharmacy
Release Date: November 6, 2021
Expiration Date: November 6, 2024
BCIDP Expiration Date: November 6, 2022
This activity is jointly provided by ProCE, LLC and the Society of Infectious Diseases Pharmacists. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-276-H01-P has been assigned to this home-study knowledge-based activity. This activity is approved for 0.75 contact hour (0.075 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certified infectious diseases pharmacist (BCIDP) credit. A BCIDP statement of credit will be issued online upon successful completion of a post-test and online evaluation. The post-test must be successfully completed in only one attempt. No partial credit will be given. BCIDP accreditation begins 11/6/2021 for this activity and is available for one year from this date.
Recertification Criteria for Infectious Diseases Pharmacy: BCIDP recertifying via continuing education are required to earn 100 hours of continuing education credit provided by the joint program offered by the Society of Infectious Diseases Pharmacists (SIDP), American College of Clinical Pharmacy (ACCP) and/or the American Society of Health-System Pharmacists (ASHP). Infectious Diseases Pharmacy Specialty Recertification Courses offered by any of the approved providers may only be completed for recertification credit up to two times, in nonconsecutive years, during the 7-year recertification cycle. Candidates should note that there are expiration dates associated with earning BPS recertification credit. BPS will only award recertification credit for modules based on the completion and submission date of the post-test assessment. For example, a module completed and submitted on October 20 of a particular year will only be credited for that year, even if the due date of the post-test is in January of the following year. View all recertification criteria on the BPS website at https://www.bpsweb.org/recertification/recertification-by-continuing-education
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed in this activity. Kira Beaulac has served on the Speakers Bureau for Allergan / Abbvie and Astellas. Jamie Wagner has no relevant conflicts to disclose.
No external support has been received for this activity.
The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.